XML 34 R25.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2022 |  | 2021
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 1,086 |  |  | $ | 20 |  |  | $ | 1,106 |  |  | $ | 1,263 |  |  | $ | 26 |  |  | $ | 1,289 |
Prolia |  | 590 |  |  | 272 |  |  | 862 |  |  | 530 |  |  | 273 |  |  | 803 |
Otezla |  | 529 |  |  | 98 |  |  | 627 |  |  | 495 |  |  | 114 |  |  | 609 |
XGEVA |  | 363 |  |  | 132 |  |  | 495 |  |  | 372 |  |  | 145 |  |  | 517 |
Aranesp |  | 128 |  |  | 230 |  |  | 358 |  |  | 149 |  |  | 247 |  |  | 396 |
Repatha |  | 142 |  |  | 167 |  |  | 309 |  |  | 139 |  |  | 133 |  |  | 272 |
KYPROLIS |  | 217 |  |  | 101 |  |  | 318 |  |  | 198 |  |  | 95 |  |  | 293 |
Neulasta |  | 205 |  |  | 42 |  |  | 247 |  |  | 360 |  |  | 55 |  |  | 415 |
Nplate |  | 162 |  |  | 126 |  |  | 288 |  |  | 156 |  |  | 117 |  |  | 273 |
Other products(1) |  | 1,044 |  |  | 583 |  |  | 1,627 |  |  | 896 |  |  | 557 |  |  | 1,453 |
Total product sales(2) |  | $ | 4,466 |  |  | $ | 1,771 |  |  | 6,237 |  |  | $ | 4,558 |  |  | $ | 1,762 |  |  | 6,320 |
Other revenues |  |  |  |  |  | 415 |  |  |  |  |  |  | 386 |
Total revenues |  |  |  |  |  | $ | 6,652 |  |  |  |  |  |  | $ | 6,706 |
|  | Nine months ended September 30,
|  | 2022 |  | 2021
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 2,965 |  |  | $ | 54 |  |  | $ | 3,019 |  |  | $ | 3,270 |  |  | $ | 87 |  |  | $ | 3,357 |
Prolia |  | 1,783 |  |  | 853 |  |  | 2,636 |  |  | 1,569 |  |  | 806 |  |  | 2,375 |
Otezla |  | 1,366 |  |  | 306 |  |  | 1,672 |  |  | 1,284 |  |  | 335 |  |  | 1,619 |
XGEVA |  | 1,122 |  |  | 408 |  |  | 1,530 |  |  | 1,061 |  |  | 412 |  |  | 1,473 |
Aranesp |  | 397 |  |  | 676 |  |  | 1,073 |  |  | 409 |  |  | 709 |  |  | 1,118 |
Repatha |  | 461 |  |  | 502 |  |  | 963 |  |  | 421 |  |  | 423 |  |  | 844 |
KYPROLIS |  | 626 |  |  | 296 |  |  | 922 |  |  | 547 |  |  | 277 |  |  | 824 |
Neulasta |  | 772 |  |  | 133 |  |  | 905 |  |  | 1,215 |  |  | 168 |  |  | 1,383 |
Nplate |  | 474 |  |  | 364 |  |  | 838 |  |  | 404 |  |  | 341 |  |  | 745 |
Other products(1) |  | 2,983 |  |  | 1,708 |  |  | 4,691 |  |  | 2,655 |  |  | 1,633 |  |  | 4,288 |
Total product sales(2) |  | $ | 12,949 |  |  | $ | 5,300 |  |  | 18,249 |  |  | $ | 12,835 |  |  | $ | 5,191 |  |  | 18,026 |
Other revenues |  |  |  |  |  | 1,235 |  |  |  |  |  |  | 1,107 |
Total revenues |  |  |  |  |  | $ | 19,484 |  |  |  |  |  |  | $ | 19,133 |
____________ (1) Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries. (2) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2022 and 2021.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration